{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T13:49:43Z","timestamp":1762868983337,"version":"3.41.2"},"reference-count":41,"publisher":"IMR Press","issue":"12","license":[{"start":{"date-parts":[[2022,12,19]],"date-time":"2022-12-19T00:00:00Z","timestamp":1671408000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rev. Cardiovasc. Med."],"abstract":"<jats:p>The racial\/ethnic disparities in cardiometabolic risk factors and cardiovascular diseases (CVD) are prominent in non-Hispanic Black adults and other United States (U.S.) sub-populations, with evidence of differential access and quality of health care. High blood pressure (BP) is the most potent and prevalent risk factor for adverse cardiovascular (CV) outcomes across all populations globally, but especially in the non-Hispanic Black adults in the U.S. The use of sodium-glucose cotransporter-2 inhibitors (SGLT2is) demonstrate favorable effects in patients with and without type 2 diabetes (T2DM) in CVD especially for heart failure (HF), as the contemporary clinical practice recommendations and standards of care advocate. The beneficial effects of SGLT2is have been most profoundly documented with HF, including reduced (HFrEF) or preserved ejection fraction (HFpEF), and chronic kidney disease (CKD) with T2DM. Given that hypertension (HTN), CVD, HF, and CKD are significantly greater in certain racial\/ethnic populations, the potential impact of SGLT2is will be more significant on the excess cardiometabolic and renal disease, especially in the Black patients. Moreover, there is a need for increased diverse representation in clinical trials. Inclusion of larger members of various racial\/ethnic populations may assure that new and emerging data accurately reflect the diversity of the U.S. population. This review highlights potential benefits of SGLT2is, as noted in the most recent literature, and their BP-lowering impact on potentially reducing CV disparities, especially in Black adults. Furthermore, this commentary emphasizes the need to increase diversity in clinical trials to reduce the disparity gaps.<\/jats:p>","DOI":"10.31083\/j.rcm2312411","type":"journal-article","created":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T08:18:32Z","timestamp":1671783512000},"source":"Crossref","is-referenced-by-count":4,"title":["Addressing Cardiovascular Disparities in Racial\/Ethnic Populations: The Blood Pressure-Lowering Effects of SGLT2 Inhibitors"],"prefix":"10.31083","volume":"23","author":[{"given":"Samar A.","family":"Nasser","sequence":"first","affiliation":[{"name":"Department of Clinical Research & Leadership, School of Medicine and Health Sciences, The George Washington University, Washington, DC 20052, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neha","family":"Arora","sequence":"first","affiliation":[{"name":"Department of Medicine, Tulane University School of Medicine, New Orleans, LA 70112, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keith C.","family":"Ferdinand","sequence":"first","affiliation":[{"name":"Department of Medicine, Tulane University School of Medicine, New Orleans, LA 70112, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"16242","published-online":{"date-parts":[[2022,12,19]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Whelton PK, Carey RM, Aronow WS, Casey DE, Collins KJ, Himmelfarb CD, et al. 2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/ PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2018; 138: e426\u2013e483.","DOI":"10.1161\/CIR.0000000000000597"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Draznin B, Aroda VR, Bakris G, Benson G, Brown FM, Freeman R, et al. Chronic Kidney Disease and Risk Management: Standards of Medical Care in Diabetes-2022. Diabetes Care. 2022; 45: S175\u2013S184.","DOI":"10.2337\/dc22-S011"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Ogunniyi MO, Commodore-Mensah Y, Ferdinand KC. Race, Ethnicity, Hypertension, and Heart Disease. Journal of the American College of Cardiology. 2021; 78: 2460\u20132470.","DOI":"10.1016\/j.jacc.2021.06.017"},{"key":"ref4","unstructured":"Tsao CW, Aday AW, Almarzooq ZI, Alonso A, Beaton AZ, Bittencourt MS, et al. Heart disease and stroke Statistics-2022 Update: A Report From the American Heart Association. Circulation. 2022; 145: e153\u2013e639."},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Corlin L, Short MI, Vasan RS, Xanthakis V. Association of the Duration of Ideal Cardiovascular Health through Adulthood with Cardiometabolic Outcomes and Mortality in the Framingham Offspring Study. JAMA Cardiology. 2020; 5: 549\u2013556.","DOI":"10.1001\/jamacardio.2020.0109"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Ferdinand KC, Reddy TK. Disparities in the COVID-19 pandemic: a clarion call for preventive cardiology. American Journal of Preventive Cardiology. 2021; 8: 100283.","DOI":"10.1016\/j.ajpc.2021.100283"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Mazimba S, Peterson PN. JAHA Spotlight on racial and ethnic disparities in cardiovascular disease. Journal of the American Heart Association. 2021; 10: e023650.","DOI":"10.1161\/JAHA.121.023650"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Ouyang F, Cheng X, Zhou W, He J, Xiao S. Increased mortality trends in patients with chronic non-communicable diseases and comorbid hypertension in the United States, 2000\u20132019. Frontiers in Public Health. 2022; 10: 753861.","DOI":"10.3389\/fpubh.2022.753861"},{"key":"ref9","unstructured":"World Health Organization. Noncommunicable diseases fact sheet. 2022. Available at: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/noncommunicable-diseases (Accessed: 5 August 2022)."},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Motairek I, Lee EK, Janus S, Farkouh M, Freedman D, Wright J, et al. Historical Neighborhood Redlining and Contemporary Cardiometabolic Risk. Journal of the American College of Cardiology. 2022; 80: 171\u2013175.","DOI":"10.1016\/j.jacc.2022.05.010"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Harper S, Riddell CA, King NB. Declining Life Expectancy in the United States: Missing the Trees for the Forest. Annual Review of Public Health. 2021; 42: 381\u2013403.","DOI":"10.1146\/annurev-publhealth-082619-104231"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Woolf SH, Masters RK, Aron LY. Changes in Life Expectancy between 2019 and 2020 in the us and 21 Peer Countries. JAMA Network Open. 2022; 5: e227067.","DOI":"10.1001\/jamanetworkopen.2022.7067"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Bailey CJ, Day C, Bellary S. Renal Protection with SGLT2 Inhibitors: Effects in Acute and Chronic Kidney Disease. Current Diabetes Reports. 2022; 22: 39\u201352.","DOI":"10.1007\/s11892-021-01442-z"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Shin H, Schneeweiss S, Glynn RJ, Patorno E. Cardiovascular Outcomes in Patients Initiating first-Line Treatment of Type 2 Diabetes with Sodium\u2013Glucose Cotransporter-2 Inhibitors Versus Metformin. Annals of Internal Medicine: A Cohort Study. 2022; 175: 927\u2013937.","DOI":"10.7326\/M21-4012"},{"key":"ref15","unstructured":"de Boer IH. Diabetes and CKD: New approaches to managing a common condition. Kidney News. 2020; 12: 1\u2013115."},{"key":"ref16","unstructured":"Patel R, McComb D, Rehman A, Soos MP. Appropriate use of SGLT2s and GLP-1RAs with insulin to reduce CVD risk in patients with diabetes. StatPearls Publishing: Treasure Island (FL). 2022."},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Kario K, Ferdinand KC, Vongpatanasin W. Are SGLT2 Inhibitors New Hypertension Drugs? Circulation. 2021; 143: 1750\u20131753.","DOI":"10.1161\/CIRCULATIONAHA.121.053709"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"van Ruiten CC, Smits MM, Kok MD, Sern\u00e9 EH, van Raalte DH, Kramer MHH, et al. Mechanisms underlying the blood pressure lowering effects of dapagliflozin, exenatide, and their combination in people with type 2 diabetes: a secondary analysis of a randomized trial. Cardiovascular Diabetology. 2022; 21: 63.","DOI":"10.1186\/s12933-022-01492-x"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Mende CW. Chronic Kidney Disease and SGLT2 Inhibitors: a Review of the Evolving Treatment Landscape. Advances in Therapy. 2022; 39: 148\u2013164.","DOI":"10.1007\/s12325-021-01994-2"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Ferdinand KC, Izzo JL, Lee J, Meng L, George J, Salsali A, et al. Antihyperglycemic and Blood Pressure Effects of Empagliflozin in Black Patients with Type 2 Diabetes Mellitus and Hypertension. Circulation. 2019; 139: 2098\u20132109.","DOI":"10.1161\/CIRCULATIONAHA.118.036568"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Baker WL, Buckley LF, Kelly MS, Bucheit JD, Parod ED, Brown R, et al. Effects of Sodium\u2010Glucose Cotransporter 2 Inhibitors on 24\u2010Hour Ambulatory Blood Pressure: a Systematic Review and Meta\u2010Analysis. Journal of the American Heart Association. 2017; 6: e005686.","DOI":"10.1161\/JAHA.117.005686"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Ye N, Jardine MJ, Oshima M, Hockham C, Heerspink HJL, Agarwal R, et al. Blood Pressure Effects of Canagliflozin and Clinical Outcomes in Type 2 Diabetes and Chronic Kidney Disease: Insights from the CREDENCE Trial. Circulation. 2021; 143: 1735\u20131749.","DOI":"10.1161\/CIRCULATIONAHA.120.048740"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022; 145: e895\u2013e1032.","DOI":"10.1161\/CIR.0000000000001073"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"American Diabetes Association. Addendum 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2020. Diabetes Care. 2020; 43: S98\u2013S110.","DOI":"10.2337\/dc20-S009"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Joseph JJ, Deedwania P, Acharya T, Aguilar D, Bhatt DL, Chyun DA, et al. Comprehensive Management of Cardiovascular Risk Factors for Adults with Type 2 Diabetes: a Scientific Statement from the American Heart Association. Circulation. 2022; 145: e722\u2013e759.","DOI":"10.1161\/CIR.0000000000001040"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Jain V, Minhas AMK, Morris AA, Greene SJ, Pandey A, Khan SS, et al. Demographic and Regional Trends of Heart Failure\u2013Related Mortality in Young Adults in the us, 1999\u20132019. JAMA Cardiology. 2022; 7: 900.","DOI":"10.1001\/jamacardio.2022.2213"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Bhattarai M, Salih M, Regmi M, Al-Akchar M, Deshpande R, Niaz Z, et al. Association of Sodium-Glucose Cotransporter 2 Inhibitors with Cardiovascular Outcomes in Patients with Type 2 Diabetes and other Risk Factors for Cardiovascular Disease. JAMA Network Open. 2022; 5: e2142078.","DOI":"10.1001\/jamanetworkopen.2021.42078"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Hoppe C, Kerr D. Minority underrepresentation in cardiovascular outcome trials for type 2 diabetes. The Lancet Diabetes & Endocrinology. 2017; 5: 13.","DOI":"10.1016\/S2213-8587(16)30324-2"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. The New England Journal of Medicine. 2013; 369: 1327\u20131335.","DOI":"10.1056\/NEJMoa1305889"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. The New England Journal of Medicine. 2015; 373: 2117\u20132128.","DOI":"10.1056\/NEJMoa1504720"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. The New England Journal of Medicine. 2013; 369: 1317\u20131326.","DOI":"10.1056\/NEJMoa1307684"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Pfeffer MA, Claggett B, Diaz R, Dickstein K, Gerstein HC, K\u00f8ber LV, et al. Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. The New England Journal of Medicine. 2015; 373: 2247\u20132257.","DOI":"10.1056\/NEJMoa1509255"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, et al. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. The New England Journal of Medicine. 2015; 373: 232\u2013242.","DOI":"10.1056\/NEJMoa1501352"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. The New England Journal of Medicine. 2016; 375: 311\u2013322.","DOI":"10.1056\/NEJMoa1603827"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"Marso SP, Bain SC, Consoli A, Eliaschewitz FG, J\u00f3dar E, Leiter LA, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. 2016; 375: 1834\u20131844.","DOI":"10.1056\/NEJMoa1607141"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Solomon SD, McMurray JV, Claggett B, de Boer RA, DeMets D, Hernandez AF, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. The New England Journal of Medicine. 2022; 387: 1089\u20131098.","DOI":"10.1056\/NEJMoa2206286"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"Jhund PS, Kondo T, Butt JH, Docherty KF, Claggett BL, Desai AS, et al. Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER. Nature Medicine. 2022; 28: 1956\u20131964.","DOI":"10.1038\/s41591-022-01971-4"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"Clark LT, Watkins L, Pi\u00f1a IL, Elmer M, Akinboboye O, Gorham M, et al. Increasing Diversity in Clinical Trials: Overcoming Critical Barriers. Current Problems in Cardiology. 2019; 44: 148\u2013172.","DOI":"10.1016\/j.cpcardiol.2018.11.002"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"Michos ED, Reddy TK, Gulati M, Brewer LC, Bond RM, Velarde GP, et al. Improving the enrollment of women and racially\/ethnically diverse populations in cardiovascular clinical trials: an ASPC practice statement. American Journal of Preventive Cardiology. 2021; 8: 100250.","DOI":"10.1016\/j.ajpc.2021.100250"},{"key":"ref40","unstructured":"Onwuanyi AE, Hutchinson BA. Regarding diversity plans to improve enrollment of participants from underrepresented racial and ethnic populations in clinical trials; Draft guidance for industry; availability [FDA-2021-D-0789]. Association of Black Cardiologists, Inc.: USA. 2022."},{"key":"ref41","doi-asserted-by":"crossref","unstructured":"DeFilippis EM, Echols M, Adamson PB, Batchelor WB, Cooper LB, Cooper LS, et al. Improving enrollment of underrepresented racial and ethnic populations in heart failure trials: A call to action from the heart failure collaboratory. JAMA Cardiology. 2022; 7: 540\u2013548.","DOI":"10.1001\/jamacardio.2022.0161"}],"container-title":["Reviews in Cardiovascular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.imrpress.com\/journal\/RCM\/23\/12\/10.31083\/j.rcm2312411","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T18:29:27Z","timestamp":1732732167000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.imrpress.com\/journal\/RCM\/23\/12\/10.31083\/j.rcm2312411"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,19]]},"references-count":41,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022]]}},"alternative-id":["S1530-6550(22)00787-6"],"URL":"https:\/\/doi.org\/10.31083\/j.rcm2312411","relation":{},"ISSN":["1530-6550","2153-8174"],"issn-type":[{"type":"print","value":"1530-6550"},{"type":"electronic","value":"2153-8174"}],"subject":[],"published":{"date-parts":[[2022,12,19]]},"article-number":"411"}}